Publication | Closed Access
Response to Lenvatinib in Children with Papillary Thyroid Carcinoma
31
Citations
19
References
2018
Year
Lenvatinib therapy is well tolerated and demonstrated clinical activity in children with advanced PTC. Lenvatinib should be considered in children with PTC that is refractory or not amenable to conventional management.
| Year | Citations | |
|---|---|---|
Page 1
Page 1